Analysis of the efficacy, role and clinical application scope of afatinib (Gitarel)

Afatinib (Afatinib) is a second-generation oral irreversible EGFR (epidermal growth factor receptor) and HER2 family inhibitor. Irreversibly binds to EGFR, HER2 and HER4 receptors, blocking receptor tyrosine kinase signaling, thereby inhibiting tumor cell proliferation, inducing apoptosis and inhibiting angiogenesis. Compared with the first-generation reversible EGFR inhibitors, afatinib has a certain ability to overcome drug-resistant mutations and can provide a more durable tumor inhibitory effect.

In terms of clinical efficacy, afatinib has shown significant anti-tumor effects in patients with non-small cell lung cancer (NSCLC) carrying EGFR sensitive mutations. Multiple clinical trials have shown that afatinib can significantly prolong progression-free survival (PFS), improve overall response rate (ORR), and improve symptom control and quality of life. Especially for patients carrying Exon 19 deletion or L858R mutation, the efficacy is more outstanding.

The indications of afatinib mainly include advanced or metastatic EGFR mutation-positive non-small cell lung cancer. It can be used as first-line treatment or continued after resistance to first-generation EGFR inhibitors. Some guidelines also recommend exploratory use in specific HER2 mutation-positive tumors or head and neck squamous cell carcinomas. Its oral administration form facilitates long-term maintenance treatment, while allowing flexibility in dosage adjustment to improve tolerability.

In clinical use, attention needs to be paid to patient tolerance and potential adverse reactions. Common side effects include rash, diarrhea, stomatitis and paronychia, etc., which can usually be controlled through dose adjustment or symptomatic treatment. In addition, afatinib should be used with caution in patients with abnormal renal and liver function, and regular monitoring of hematological and biochemical indicators is recommended. Taken together, afatinib has played a significant role in EGFR-driven NSCLC, providing an important option for precise targeted therapy.

Reference link:https://www.drugs.com